Urinary complement biomarkers, particularly urinary C3d, C4, CFI and C5b-9 have shown promise as reliable tests to identify active lupus nephritis, monitor disease activity, assess treatment response, and predict disease flare in a few studies. This evidence concerns the gene C4A and lupus nephritis.